Acquired resistance of EGFR-mutant lung Adenocarcinomas to Afatinib plus Cetuximab is associated with activation of mTORC1 Journal Article


Authors: Pirazzoli, V.; Nebhan, C.; Song, X.; Wurtz, A.; Walther, Z.; Cai, G.; Zhao, Z.; Jia, P.; de Stanchina, E.; Shapiro, E. M.; Gale, M.; Yin, R.; Horn, L.; Carbone, D. P.; Stephens, P. J.; Miller, V.; Gettinger, S.; Pao, W.; Politi, K.
Article Title: Acquired resistance of EGFR-mutant lung Adenocarcinomas to Afatinib plus Cetuximab is associated with activation of mTORC1
Abstract: Patients with EGFR-mutant lung adenocarcinomas (LUADs) who initially respond to first-generation tyrosine kinase inhibitors (TKIs) develop resistance to these drugs. A combination of the irreversible TKI afatinib and the EGFR antibody cetuximab can be used to overcome resistance to first-generation TKIs; however, resistance to this drug combination eventually emerges. We identified activation of the mTORC1 signaling pathway as a mechanism of resistance to dual inhibition of EGFR in mouse models. The addition of rapamycin reversed resistance in vivo. Analysis of afatinib-plus-cetuximab-resistant biopsy specimens revealed the presence of genomic alterations in genes that modulate mTORC1 signaling, including NF2 and TSC1. These findings pinpoint enhanced mTORC1 activation as a mechanism of resistance to afatinib plus cetuximab and identify genomic mechanisms that lead to activation of this pathway, revealing a potential therapeutic strategy for treating patients with resistance to these drugs. © 2014 The Authors.
Keywords: controlled study; protein phosphorylation; treatment response; gene mutation; human cell; nonhuman; nuclear magnetic resonance imaging; animal cell; mouse; phenotype; vasculotropin receptor; animal experiment; animal model; in vivo study; cetuximab; protein tyrosine kinase inhibitor; lung adenocarcinoma; genetic engineering; xenograft; heterozygosity loss; rapamycin; thyroid transcription factor 1; afatinib; human; priority journal; article
Journal Title: Cell Reports
Volume: 7
Issue: 4
ISSN: 2211-1247
Publisher: Cell Press  
Date Published: 2014-05-22
Start Page: 999
End Page: 1008
Language: English
DOI: 10.1016/j.celrep.2014.04.014
PROVIDER: scopus
PMCID: PMC4074596
PUBMED: 24813888
DOI/URL:
Notes: Cell Rep. -- Export Date: 8 July 2014 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors